Press releases
- Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
- Flagship Pioneering Unveils Prologue Medicines to Unlock the Therapeutic Potential of the Viral Proteome
- Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024
- Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
More ▼
Key statistics
As of last trade, Seres Therapeutics Inc (1S9:STU) traded at 0.6442, 29.59% above the 52 week low of 0.4971 set on Apr 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.6358 |
---|---|
High | 0.6442 |
Low | 0.6358 |
Bid | 0.6688 |
Offer | 0.684 |
Previous close | 0.6554 |
Average volume | 1.04k |
---|---|
Shares outstanding | 151.45m |
Free float | 150.78m |
P/E (TTM) | -- |
Market cap | 106.29m USD |
EPS (TTM) | -0.6062 USD |
Data delayed at least 15 minutes, as of Jul 03 2024.
More ▼